FDA COVID-19 RESPONSE
FDA is working with U.S. government partners, including CDC, and international partners to address the pandemic.
Featured Topics
New Era of Smarter Food Safety
A new approach to food safety that recognizes and builds on the progress made in the past but looks towards what processes and tools will be needed for the future.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Sep 16
Drew’s Organics, LLC Issues Voluntary Recall of Aldi Simply Nature Organic Poppy Seed Dressing for Potential Clostridium botulinum Contamination
Food & Beverages
Sep 16
Baker Farms Recalls Various Brand Name of Kale Due to Listeria Monocytogenes Contamination
Food & Beverages
Sep 16
Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (Varenicline) Tablets Due to N-Nitroso Varenicline Content
Drugs
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Continues Collaboration with Drug Compounders as Second Anniversary of Compounding Quality Center of Excellence Approaches
The Compounding Quality Center of Excellence works with outsourcing facilities, pharmacy compounders to improve the quality of compounded prescription drugs.
FDA’s National Center for Toxicological Research Celebrates Half a Century of Cutting-Edge Research
NCTR is celebrating 50 years of scientific achievements including the groundbreaking research we have done—and continue to do—in support of the FDA’s mission.
FDA Seeks Patient Insight: Call for Applications for the Patient Engagement Collaborative
The FDA is announcing the call for applications for the next cohort of the Patient Engagement Collaborative.
Recently Published Guidances
Sep 17
Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry
Drugs
Sep 17
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3)
Drugs
Sep 16
Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry
Biologics, Drugs